JUBLINGREA — Jubilant Ingrevia Ltd. SWOT Analysis

Strengths Diversified specialty-chemicals portfolio with 130+ products across 35+ chemistry platforms. Serves 1,600+ customers in 63 countries, giving it a broad global customer base. Strong presence across pharma, agrochemicals, nutrition, consumer and industrial applications. Integrated chemistry capabilities and established manufacturing infrastructure. CDMO business provides potential for higher-value, customer-specific solutions. FY26 consolidated revenue increased to ₹4,388 Cr, while EBITDA rose to ₹607 Cr and PAT to ₹278 Cr. Weaknesses Earnings remain exposed to specialty-chemical pricing and realization cycles. Several products can experience margin pressure when raw-material costs rise faster than selling prices. Manufacturing shutdowns or operational issues can affect volumes, as seen previously at the Nira plant. Chemical manufacturing is relatively capital- and energy-intensive. International operations expose the company to currency and global-demand fluctuations. Opportunities Expansion of CDMO/customised specialty chemicals for global pharmaceutical and agrochemical customers. Growing demand for India-based chemical supply chains and import substitution. Higher-value products in nutrition, life sciences and advanced specialty chemistry. Increasing global interest in sustainable chemistry and bio-based products. Expansion into semiconductor and other specialised industrial applications. Threats Competition from Chinese and other Asian chemical manufacturers. Volatility in raw-material and energy prices. Global chemical-cycle downturns can pressure realizations and capacity utilisation. Environmental, safety and regulatory requirements can increase compliance costs. Customer concentration/product-specific demand cycles and international trade disruptions.